Sunday, June 24, 2012

Research from University of Connecticut in the area of pancreatic cancer published

By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators publish new report on Pancreatic Cancer. According to news reporting from Farmington, Connecticut, by NewsRx journalists, researchers stated "To investigate the inhibitory role of pterostilbene in pancreatic cancer, we conducted a genomic analysis of pterostilbene-treated pancreatic cancer cells. We also investigated the effect of pterostilbene upon the carcinogenic markers, manganese superoxide dismutase, cytochrome C, Smac/DIABLO, and STAT3 phosphorylation in vitro."

The news correspondents obtained a quote from the research by the authors from the University of Connecticut, "The antiproliferative effects of pterostilbene were further evaluated in an in vivo model. Pancreatic cancer cells were treated with pterostilbene and evaluated with DNA microarray analysis. Pterostilbene-treated cells were analyzed for cytochrome C, Smac/DIABLO, manganese superoxide dismutase (MnSOD)/antioxidant activity, and STAT3 phosphorylation using ELISA. Data were statistically analyzed using ANOVA. Pterostilbene was then administered to nude mice for 8 weeks, and tumor growth rates were recorded and statistically analyzed. Microarray analysis of pterostilbene-treated cells revealed upregulation of pro-apoptosis genes. In vitro, pterostilbene treatment altered levels of phosphorylated STAT3, MnSOD/antioxidant activity, cytochrome C, and Smac/DIABLO. In nude mice, oral pterostilbene inhibited tumor growth rates. Pterostilbene alters gene expression in pancreatic cancer and increases the antiproliferative markers cytochrome C, Smac/DIABLO, and MnSOD/antioxidant activity. It was also shown to inhibit phosphorylated STAT3, a marker of accelerated tumorigenesis, and decrease pancreatic tumor growth in vivo."

According to the news reporters, the researchers concluded: "Further studies are warranted to elucidate the effects of pterostilbene in humans."

For more information on this research see: Genomic Analysis of Pterostilbene Predicts Its Antiproliferative Effects Against Pancreatic Cancer In Vitro and In Vivo. Journal of Gastrointestinal Surgery, 2012;16(6):1136-1143. Journal of Gastrointestinal Surgery can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Elsevier - www.elsevier.com; Journal of Gastrointestinal Surgery - www.elsevier.com/wps/product/cws_home/622198)

Our news journalists report that additional information may be obtained by contacting D.E. McCormack, University of Connecticut, Center Hlth, Farmington, CT 06030, United States (see also Pancreatic Cancer).

Keywords for this news article include: Antioxidants, Genetics, Oncology, Farmington, Connecticut, Cytochromes, Hemeproteins, United States, Oxidoreductases, Gastroenterology, Pancreatic Cancer, Protective Agents, Pancreatic Neoplasms, Superoxide Dismutase, Enzymes and Coenzymes, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC

To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .

jim irsay the new ipad apple announcement indianapolis colts joseph kony joseph kony higgs boson

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.